Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGAV | P06756 | 1/20 | 0.35 |
| ▸ | ITGB6 | P18564 | 1/20 | 0.35 |
| ▸ | ITGB8 | P26012 | 1/20 | 0.35 |
| ▸ | NNMT | P40261 | 1/20 | 0.35 |
| ▸ | GRM5 | P41594 | 1/20 | 0.33 |
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.33 |
| ▸ | ASIC3 | Q9UHC3 | 1/20 | 0.32 |
| ▸ | PARP1 | P09874 | 1/20 | 0.32 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.32 |
| ▸ | HTR2C | P28335 | 1/20 | 0.32 |
| ▸ | HTR2B | P41595 | 1/20 | 0.32 |
| ▸ | DPP4 | P27487 | 1/20 | 0.30 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23186733 | 0.82 | NNMT (0.35) | NNMTGRM5ASIC3 | |
| SCHEMBL3132352 | 0.77 | PARP10 (0.41) | PARP1PARP10 | |
| SCHEMBL1662286 | 0.75 | KIF11 (0.37) | — | |
| SCHEMBL26013992 | 0.72 | NNMT (0.38) | ITGAVITGB6ITGB8NNMT | |
| SCHEMBL30219628 | 0.72 | NNMT (0.41) | NNMTGRM5ASIC3 | |
| SCHEMBL28986310 | 0.72 | NNMT (0.41) | NNMTGRM5ASIC3 | |
| SCHEMBL13355386 | 0.72 | NNMT (0.38) | ITGAVNNMTGRM5ASIC3PARP1 | |
| SCHEMBL17077911 | 0.71 | GRM5 (0.38) | GRM5MALT1 | |
| SCHEMBL19553066 | 0.71 | PARP10 (0.36) | MALT1PARP1PARP10 | |
| Hydrochloric Acid SCHEMBL3132492 | 0.71 | HTR2C (0.50) | ASIC3HTR2CHTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170240566-A1 | AMINO-SUBSTITUTED ANNULATED PYRIMIDINES AND USE THEREOF | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-08-24 | — | — | US | disclosed |
| EP-3186251-A1 | SUBSTITUTED ANNULATED PYRIMIDINES AND USE THEREOF | Bayer Pharma Aktiengesellschaft (DE) | 2017-07-05 | — | — | EP | disclosed |
| WO-2016030362-A1 | SUBSTITUTED ANNULATED PYRIMIDINES AND USE THEREOF | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-03-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170240566-A1 | AMINO-SUBSTITUTED ANNULATED PYRIMIDINES AND USE THEREOF | TYMP, TYMS, DPYD | ITGAV 4563/4885ITGB6 4002/4885ITGB8 4459/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.